Trial Profile
A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With Acute Myeloid Leukemia (AML) Who Are Not Transplantation Candidates
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 27 Jan 2021 Status changed from active, no longer recruiting to completed.
- 08 May 2020 Planned primary completion date changed from 1 Oct 2020 to 1 Jul 2020.
- 08 May 2020 Status changed from recruiting to active, no longer recruiting.